Neuphoria Therapeutics Inc. (NEUP)

Neuphoria Therapeutics Income Statement

Financials in millions USD. Fiscal year is July - June.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2025	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Operating Revenue	15.65	15.65	-	-	0.18	-
Other Revenue	-	-	-	-	3.99	0.7
Revenue	15.65	15.65	-	-	4.17	0.7
Revenue Growth (YoY)	-	-	-	-	499.60%	-66.32%
Cost of Revenue	-	-	-	-	11.02	4.32
Gross Profit	15.65	15.65	-	-	-6.85	-3.62
Selling, General & Admin	7.97	7.77	8.47	8.91	5.28	4.23
Research & Development	10.59	8.71	9.32	12.65	-	-
Other Operating Expenses	-	-	-	-	-0	-0.15
Operating Expenses	18.56	16.48	17.8	21.56	5.27	4.08
Operating Income	-2.91	-0.83	-17.8	-21.56	-12.12	-7.7
Interest Expense	-	-	-	-	-0.02	-1.07
Interest & Investment Income	0.27	0.17	0.22	0.32	0.01	0
Currency Exchange Gain (Loss)	-0.2	-0.41	-0.21	0.31	0.25	0.81
Other Non Operating Income (Expenses)	-7.24	-	-	-	-2.59	-1.22
EBT Excluding Unusual Items	-10.08	-1.08	-17.79	-20.93	-14.48	-9.18
Gain (Loss) on Sale of Investments	0.24	0.24	2.21	-0.59	-	-
Gain (Loss) on Sale of Assets	-	-	-	-	-0	-0.02
Other Unusual Items	-	-	-	-	-0.65	2.54
Pretax Income	-9.84	-0.84	-15.58	-21.52	-15.12	-6.66
Income Tax Expense	-0.37	-0.47	-0.09	-0.14	-0.13	-0.14
Earnings From Continuing Operations	-9.47	-0.37	-15.49	-21.38	-14.99	-6.52
Net Income	-9.47	-0.37	-15.49	-21.38	-14.99	-6.52
Net Income to Common	-9.47	-0.37	-15.49	-21.38	-14.99	-6.52
Shares Outstanding (Basic)	2	2	1	1,469	1,353	780
Shares Outstanding (Diluted)	2	2	1	1,469	1,353	780
Shares Change (YoY)	-99.94%	95.06%	-99.94%	8.53%	73.52%	43.14%
EPS (Basic)	-5.09	-0.23	-18.62	-0.01	-0.01	-0.01
EPS (Diluted)	-5.09	-0.23	-18.62	-0.01	-0.01	-0.01
Free Cash Flow	0.72	0.08	-14.68	-14.64	-14.99	-5.65
Free Cash Flow Per Share	0.39	0.05	-17.64	-0.01	-0.01	-0.01
Gross Margin	100.00%	100.00%	-	-	-164.21%	-
Operating Margin	-18.62%	-5.30%	-	-	-290.62%	-1107.29%
Profit Margin	-60.52%	-2.36%	-	-	-359.34%	-937.11%
Free Cash Flow Margin	4.57%	0.49%	-	-	-359.30%	-812.46%
EBITDA	-2.25	-0.17	-17.13	-20.9	-11.49	-7
EBITDA Margin	-14.38%	-1.06%	-	-	-275.36%	-
D&A For EBITDA	0.66	0.66	0.66	0.66	0.64	0.7
EBIT	-2.91	-0.83	-17.8	-21.56	-12.12	-7.7
EBIT Margin	-18.62%	-5.30%	-	-	-290.62%	-

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q